It's unclear how many doses of Novavax's jab – its only commercially available product after 35 years – went unused.
Under the amended agreement, Novavax will also provide Canada with fewer doses of its vaccine on a revised delivery schedule.
In May, Novavax adopted a more positive outlook and announced a sweeping cost-cutting plan alongside its first-quarter earnings report.
Novavax's stock price jumped around 30% on that news, but Wall Street hasn't entirely bought into the recovery plan: The company's stock price is still down roughly 15% since the start of the year after shedding more than 90% of its value in 2022.
Novavax still faces a number of challenges ahead, including competing with Pfizer and Moderna in the commercial Covid vaccine market and a pending $700 million arbitration over a canceled vaccine purchase agreement.
Persons:
–, Novavax
Organizations:
SEC, Canadian, Securities and Exchange Commission, Pfizer, Moderna
Locations:
Maryland, Canada